Research programme: phosphatidylinositol 3-kinase inhibitors - Roche

Drug Profile

Research programme: phosphatidylinositol 3-kinase inhibitors - Roche

Alternative Names: PI 509; PI 516; PI-540; PI-620; RO2492

Latest Information Update: 07 Mar 2011

Price : $50

At a glance

  • Originator Astellas Pharma; Cancer Research UK; Ludwig Institute for Cancer Research; The Institute of Cancer Research
  • Developer Roche
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Haematological malignancies; Rheumatoid arthritis
  • Discontinued Viral infections

Most Recent Events

  • 07 Mar 2011 Preclinical development is ongoing in United Kingdom
  • 27 May 2008 Piramed has been acquired and merged into Roche
  • 16 Apr 2008 Pharmacodynamics data from a preclinical trial in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top